Peng Ke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peng Ke has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Jihao Zhou
Department of Hematology, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology)
3 shared publicationsJunjie Hou
Department of Hematology, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology)
3 shared publicationsChun Feng
Department of Hematology, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology)
2 shared publicationsGuoqiang Li
Department of Hematology, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology)
2 shared publicationsJialing Lu
Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
2 shared publicationsBeibei Qu
Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 15 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1913000
Case Report: Severe mixed autoimmune hemolytic anemia associated with acute cytomegalovirus infection in an immunocompetent adult
Background: Cytomegalovirus (CMV)-associated hemolytic anemia (HA) is rare in immunocompetent hosts and may present with heterogeneous serologic phenotypes, including direct antiglobulin test (DAT)-negative hemolysis, warm autoimmune hemolytic anemia (AIHA), cold antibody-mediated AIHA, and rarely mixed AIHA. Because mixed AIHA requires evidence of both warm autoantibodies and clinically significant cold autoantibody activity, this phenotype may be underrecognized without comprehensive immunohematologic testing. Case presentation: We report a case of CMV-associated HA that was diagnosed as mixed AIHA by comprehensive immunohematologic assessment and successfully managed with combination therapy. A 59-year-old immunocompetent man presented with a 7-day history of fever, sore throat, and fatigue. Initial evaluation revealed marked hepatocellular and cholestatic liver injury, positive CMV IgM with negative CMV IgG, and serum CMV DNA of 2.28 × 10 5 IU/mL. After exclusion of common viral and autoimmune causes, acute CMV hepatitis was clinically diagnosed. On hospital day 4, he developed dark brown urine, with hemoglobin falling to 40 g/L and laboratory evidence of acute hemolysis. Extended DAT revealed IgG, IgA, IgM, and C3d coating of erythrocytes, and cold agglutinin testing identified an IgM cold agglutinin with a titer of 1:128 and thermal amplitude extending to 37 °C, supporting severe CMV-associated mixed AIHA. After antiviral therapy, immunomodulatory and supportive treatment, hemolysis was controlled, and hemoglobin stabilized without further transfusion. Conclusions: CMV-associated HA may rarely present as severe mixed AIHA in immunocompetent adults. In severe or atypical cases, comprehensive immunohematologic evaluation beyond routine DAT, including extended DAT, cold agglutinin titration, and thermal amplitude testing, is essential for accurate subtyping. In severe cases, early integrated therapy targeting both CMV replication and immune-mediated hemolysis may be required.
- 15 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1913000
Open AccessCase Report: Severe mixed autoimmune hemolytic anemia associated with acute cytomegalovirus infection in an immunocompetent adult
Background: Cytomegalovirus (CMV)-associated hemolytic anemia (HA) is rare in immunocompetent hosts and may present with heterogeneous serologic phenotypes, including direct antiglobulin test (DAT)-negative hemolysis, warm autoimmune hemolytic anemia (AIHA), cold antibody-mediated AIHA, and rarely mixed AIHA. Because mixed AIHA requires evidence of both warm autoantibodies and clinically significant cold autoantibody activity, this phenotype may be underrecognized without comprehensive immunohematologic testing. Case presentation: We report a case of CMV-associated HA that was diagnosed as mixed AIHA by comprehensive immunohematologic assessment and successfully managed with combination therapy. A 59-year-old immunocompetent man presented with a 7-day history of fever, sore throat, and fatigue. Initial evaluation revealed marked hepatocellular and cholestatic liver injury, positive CMV IgM with negative CMV IgG, and serum CMV DNA of 2.28 × 10 5 IU/mL. After exclusion of common viral and autoimmune causes, acute CMV hepatitis was clinically diagnosed. On hospital day 4, he developed dark brown urine, with hemoglobin falling to 40 g/L and laboratory evidence of acute hemolysis. Extended DAT revealed IgG, IgA, IgM, and C3d coating of erythrocytes, and cold agglutinin testing identified an IgM cold agglutinin with a titer of 1:128 and thermal amplitude extending to 37 °C, supporting severe CMV-associated mixed AIHA. After antiviral therapy, immunomodulatory and supportive treatment, hemolysis was controlled, and hemoglobin stabilized without further transfusion. Conclusions: CMV-associated HA may rarely present as severe mixed AIHA in immunocompetent adults. In severe or atypical cases, comprehensive immunohematologic evaluation beyond routine DAT, including extended DAT, cold agglutinin titration, and thermal amplitude testing, is essential for accurate subtyping. In severe cases, early integrated therapy targeting both CMV replication and immune-mediated hemolysis may be required.
- 3 August 2026
- Published by S. Karger AG in Acta Haematologica
- p. 1-9
Isolated Myeloid Sarcoma of the Thoracic Spine as Initial Presentation of Acute Promyelocytic Leukemia: A Case Report and Literature Review
Introduction: Acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia, typically presents with severe bleeding. However, the occurrence of APL with isolated myeloid sarcoma (MS) as the sole initial presentation is extremely rare, lacking typical clinical and laboratory features, which complicates diagnosis and management. Case Presentation: A 45-year-old male was admitted for 2-month lower back pain. Spinal MRI showed T10 vertebral signal changes; histopathology confirmed the vertebral mass was myeloid origin, with PML::RARα fusion detected via PCR. Initial blood counts, coagulation tests, and bone marrow (BM) examinations were normal. However, 21 days postoperatively, the patient’s platelet count and fibrinogen level declined. A subsequent BM examination revealed abundant abnormal promyelocytes, and FISH confirmed the presence of the PML::RARα fusion gene, diagnosing APL with MS and central nervous system (CNS) involvement. He achieved complete remission with all-trans retinoic acid-based chemotherapy. Conclusion: This is a rare case of isolated thoracic vertebra promyelocytic sarcoma as the initial symptom, which later progressed to APL with MS and CNS involvement. Additionally, we performed a comprehensive literature review of 13 other cases of APL with spinal MS at the time of diagnosis. In aggregate, APL presenting with spinal MS as the sole initial manifestation is extremely rare.
- 3 August 2026
- Published by S. Karger AG in Acta Haematologica
- p. 1-9
Isolated Myeloid Sarcoma of the Thoracic Spine as Initial Presentation of Acute Promyelocytic Leukemia: A Case Report and Literature Review
Introduction: Acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia, typically presents with severe bleeding. However, the occurrence of APL with isolated myeloid sarcoma (MS) as the sole initial presentation is extremely rare, lacking typical clinical and laboratory features, which complicates diagnosis and management. Case Presentation: A 45-year-old male was admitted for 2-month lower back pain. Spinal MRI showed T10 vertebral signal changes; histopathology confirmed the vertebral mass was myeloid origin, with PML::RARα fusion detected via PCR. Initial blood counts, coagulation tests, and bone marrow (BM) examinations were normal. However, 21 days postoperatively, the patient’s platelet count and fibrinogen level declined. A subsequent BM examination revealed abundant abnormal promyelocytes, and FISH confirmed the presence of the PML::RARα fusion gene, diagnosing APL with MS and central nervous system (CNS) involvement. He achieved complete remission with all-trans retinoic acid-based chemotherapy. Conclusion: This is a rare case of isolated thoracic vertebra promyelocytic sarcoma as the initial symptom, which later progressed to APL with MS and CNS involvement. Additionally, we performed a comprehensive literature review of 13 other cases of APL with spinal MS at the time of diagnosis. In aggregate, APL presenting with spinal MS as the sole initial manifestation is extremely rare.
- Open Access
- 6 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1664498
Case Report: Severe autoimmune hemolytic anemia in an elderly patient caused by warm-reactive IgG and IgA autoantibodies
Background: Autoimmune Hemolytic anemia (AIHA) a relatively uncommon form of hemolytic anemia, which is characterized by the presence of autoantibodies directed against erythrocyte surface antigens, most frequently of the IgG isotype. A positive Direct Antiglobulin Test (DAT) is a key diagnostic criterion for AIHA. However, when hemolysis involves multiple autoantibodies, the standard DAT (polyspecific, anti-IgG + C3) may fail to detect certain antibodies, potentially delaying appropriate treatment. Cases presentation: We reported one patient with severe AIHA mediated by IgG and IgA autoantibodies was successfully treated with Multi-drug combination regimens. A 58-year-old female was admitted to the hospital presenting with a history of fatigue, jaundice and soy sauce-colored urine for one day. Upon admission, a complete blood count revealed a critically low hemoglobin level of 41 g/L and a life-threatening condition. Initially diagnosed with IgG-mediated AIHA via standard DAT, the patient showed suboptimal response to glucocorticoids, intravenous immunoglobulin (IVIG), and transfusion support. Subsequently, through the extended DAT (monospecific, anti-IgA, anti-IgG, anti-IgM, and anti-C3) test results, the patient was diagnosed as severe AIHA mediated by IgG and IgA. Based on extended DAT results, the treatment plan was modified to include combination therapy with dexamethasone, rituximab, cyclosporine, and bortezomib, alongside intensified plasma exchange. Conclusions: The extended DAT testing is recommended for all patients with clinical and laboratory evidence of acute hemolysis. Early detection helps in avoiding further investigations and provide efficient management. Severe AIHA mediated by multiple autoantibodies requires early intensive combination therapy, including immunosuppressive agents, IVIG and plasma exchange.
- 6 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1664498
Open AccessCase Report: Severe autoimmune hemolytic anemia in an elderly patient caused by warm-reactive IgG and IgA autoantibodies
Background: Autoimmune Hemolytic anemia (AIHA) a relatively uncommon form of hemolytic anemia, which is characterized by the presence of autoantibodies directed against erythrocyte surface antigens, most frequently of the IgG isotype. A positive Direct Antiglobulin Test (DAT) is a key diagnostic criterion for AIHA. However, when hemolysis involves multiple autoantibodies, the standard DAT (polyspecific, anti-IgG + C3) may fail to detect certain antibodies, potentially delaying appropriate treatment. Cases presentation: We reported one patient with severe AIHA mediated by IgG and IgA autoantibodies was successfully treated with Multi-drug combination regimens. A 58-year-old female was admitted to the hospital presenting with a history of fatigue, jaundice and soy sauce-colored urine for one day. Upon admission, a complete blood count revealed a critically low hemoglobin level of 41 g/L and a life-threatening condition. Initially diagnosed with IgG-mediated AIHA via standard DAT, the patient showed suboptimal response to glucocorticoids, intravenous immunoglobulin (IVIG), and transfusion support. Subsequently, through the extended DAT (monospecific, anti-IgA, anti-IgG, anti-IgM, and anti-C3) test results, the patient was diagnosed as severe AIHA mediated by IgG and IgA. Based on extended DAT results, the treatment plan was modified to include combination therapy with dexamethasone, rituximab, cyclosporine, and bortezomib, alongside intensified plasma exchange. Conclusions: The extended DAT testing is recommended for all patients with clinical and laboratory evidence of acute hemolysis. Early detection helps in avoiding further investigations and provide efficient management. Severe AIHA mediated by multiple autoantibodies requires early intensive combination therapy, including immunosuppressive agents, IVIG and plasma exchange.
- Open Access
- 23 August 2024
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 1-5
Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease
- 23 August 2024
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 1-5
Open AccessSafety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease